乙二胺四乙酸螯合疗法导致的儿科死亡
Pediatric fatality secondary to EDTA chelation.
作者信息
Baxter Arla J, Krenzelok Edward P
机构信息
Pittsburgh Poison Center, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.
出版信息
Clin Toxicol (Phila). 2008 Dec;46(10):1083-4. doi: 10.1080/15563650701261488.
BACKGROUND
Chelation therapy has emerged as a popular treatment modality to remove heavy metals that are thought to cause autism. We report a fatality that occurred as a consequence of chelation therapy for autism when the incorrect form of EDTA was administered.
CASE REPORT
A five-year-old autistic male was being chelated in a physician's office. While receiving his third treatment he went into cardiac arrest. It was not determined until after the child's death that he had been given edetate disodium rather than edetate calcium disodium, causing profound hypocalcemia and triggering the cardiac events that led to his death.
DISCUSSION
In 1991, the CDC recommended using only edetate calcium disodium, not edetate disodium, to children because edetate disodium may induce tetany and possible hypocalcemia as illustrated in this case.
CONCLUSION
The use of chelation therapy in autistic children has not been validated and can have tragic consequences.
背景
螯合疗法已成为一种流行的治疗方式，用于清除被认为会导致自闭症的重金属。我们报告了一例因自闭症螯合疗法而导致的死亡病例，当时使用了错误形式的乙二胺四乙酸（EDTA）。
病例报告
一名五岁的自闭症男性在医生办公室接受螯合治疗。在接受第三次治疗时，他心脏骤停。直到孩子死后才确定他被给予的是乙二胺四乙酸二钠而非乙二胺四乙酸钙二钠，这导致了严重的低钙血症，并引发了导致他死亡的心脏事件。
讨论
1991年，美国疾病控制与预防中心（CDC）建议仅对儿童使用乙二胺四乙酸钙二钠，而非乙二胺四乙酸二钠，因为如本病例所示，乙二胺四乙酸二钠可能会诱发手足搐搦和可能的低钙血症。
结论
在自闭症儿童中使用螯合疗法尚未得到验证，并且可能会产生悲惨后果。
Zotero 插件